摘要
目的探讨替罗非班对老年非ST段抬高型急性冠脉综合征(NSTE-ACS)患者血小板聚集和炎性标志物浓度及预后的影响。方法选择2013-04~2015-04该院收治的NSTE-ACS患者86例,随机分为观察组和对照组,各43例。两组患者均予常规药物阿司匹林、氢氯吡格雷及伊诺肝素治疗。观察组同时加用替罗非班治疗,持续治疗1周。对两组血小板聚集情况、炎性标志物浓度、临床疗效及预后情况进行对比分析。结果观察组炎性标志物浓度明显低于对照组,差异有统计学意义(P<0.01);观察组临床疗效优于对照组(P<0.05)。观察组血小板聚集率与心血管事件发生率明显低于对照组(P<0.05)。结论替罗非班治疗老年NSTE-ACS患者疗效确切,可有效减轻心肌损伤,降低血小板聚集率及炎性标志物浓度,改善临床预后。
Objective To investigate the effect of tirofiban platelet aggregation and inflammatory markers in the elderly patients with non-ST segment elevation acute coronary syndrome（NSTE-ACS）.Methods 86 NSTE-ACS patients admitted to our hospital from April 2013 to April 2015 were randomly divided into the observation group and the control group, with 43 cases in each group. Both of the two groups were given the routine treatment of aspirin, clopidogrel and enoxaparin, besides this treatment the observation group was treated with tirofiban for 1 week. The platelet aggregation and inflammatory markers, the clinical effect and prognosis were compared between the two groups.Results The inflammatory markers of the observation group were significantly lower than those of the control group（P〈0.01）. The clinical efficiency of the observation group was significantly higher than that of the control group（P〈0.05）; The platelet aggregation rate and the incidence of cardiovascular events in the observation group were significantly lower than those in the control group（P〈0.05）. Conclusion Tirofiban can effectively reduce the myocardial injury, the rate of platelet aggregation and the concentration of inflammatory markers, and improve the clinical prognosis for the elderly patients with NSTE-ACS.
出处
《中国临床新医学》
2017年第9期875-877,共3页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
替罗非班
急性冠脉综合征
炎性标志物
预后
Tirofiban
Acute coronary syndrome
Inflammatory markers
Prognosis
